Washington, DC: In a recent randomized clinical trial of hospitalized patients with COVID-19 and cardio-metabolic risk factors, the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin did.
Dapagliflozin was well-tolerated irrespective of kidney function in COVID-19 patients who were hospitalized, as per the recent randomized clinical trial.
USA: In an Intention-to-treat analysis of children, adolescents, and young adults with type 2 diabetes who received dapagliflozin with the standard of care treatment there was no significant change in.
AstraZeneca Pharma India announced that the company and Abbott Healthcare have on 27 May 2021 mutually terminated the Distribution Agreement for distribution of Dapagliflozin, an innovative Type 2 diabetes medicine in India under brand name Gledepa and the combination of Dapagliflozin with Metformin under the brand name Gledepa Met.
AstraZeneca India will continue to independently market Dapagliflozin, the combinations of Dapagliflozin and Metformin as well as Dapagliflozin and Saxagliptin in India under the brand names Forxiga Xigduo and Qtern respectively.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Read more about Sun Pharma acquires trademarks, patent license for dapagliflozin from AstraZeneca on Business Standard. The drug major has acquired the rights to trademarks